$VSTM News

What Verastem (VSTM)'s Trial Update Means For Shareholders

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

BTIG Reiterates Buy on Verastem, Maintains $24 Price Target

Mizuho Maintains Outperform on Verastem, Raises Price Target to $14

Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap?

Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says

Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Jefferies Maintains Buy on Verastem, Raises Price Target to $13

RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19

Verastem: A Real Pancreatic Cancer Drug, Arriving Second

BTIG Maintains Buy on Verastem, Raises Price Target to $24

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers - Slideshow

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem cancer drug shows early promise in small study

Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know

Verastem Cancer Drug Shows Responses in Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan